Sirolimus-based, calcineurin-inhibitor sparing immunotherapy, long-term (6-year) results.
At the Albany Medical Center, we have a long-term experience, mean follow-up of 75 months, in 50 renal transplant recipients treated with maintenance sirolimus, prednisone and a calcineurin-inhibitor sparing immunosuppressive regimen. One-year patient and graft survival was 98% and six-year patient and graft survival was 82% and 72% respectively. The rate of early acute rejection (<3 months) was only 10%. Furthermore, no late (>3 months) acute rejection episodes developed despite calcineurin-inhibitor dose minimization. In addition, recipient mean serum creatinine remained stable at 1.6 mg/dl throughout the 6-year follow-up period. Sirolimus is an effective maintenance immunosuppressive agent that safely allows for a reduction in calcineurin-inhibitor dosing.
Conti
David J
DJ
Department of Surgery, Albany Medical College, Albany, New York 12208-3479, USA. contid@mail.amc.edu
Petrov
Roman
R
Elbalhoul
Ossama
O
Gallichio
Michael
M
D000328:Adult; D000368:Aged; D065095:Calcineurin Inhibitors; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007167:Immunotherapy; D016030:Kidney Transplantation / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage*; D016559:Tacrolimus / Q000008:administration & dosage
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D003404:Creatinine; D011241:Prednisone; D020123:Sirolimus; D016559:Tacrolimus